Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Jul 13, 2023 6:18pm
269 Views
Post# 35540296

Context is everything

Context is everythingThanks to Noteable for keeping us apprised of supply and demand in the market for ONCY assets, as well as the regulatory environment, not to mention science developments in diverse onco-virus opportunities. 

All of these contextual elements are lined up perfectly, like the solar system in a dramatic arrangement with all the planets visible at once. Combined with the apparently undefeated track record of pela in combination trials, we have stunning opportunties in front of us.

Remember folks, the Pan Can announcement completely debunked and laid to rest any complaining about pela and ONCY not really being up to the task that it set itself. We have been totally verified and legitimized. Now it is time to be monetized. 
<< Previous
Bullboard Posts
Next >>